BS_ZR96A4FH
DNET
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- DNET
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- DNET
- age_years
- 4.214
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.514
- PANCREAS_BETA_CELLS+0.385
- SPERMATOGENESIS+0.329
- APICAL_SURFACE+0.299
- MYOGENESIS+0.233
- HEDGEHOG_SIGNALING+0.223
- BILE_ACID_METABOLISM+0.172
- ESTROGEN_RESPONSE_LATE+0.162
- ESTROGEN_RESPONSE_EARLY+0.127
- XENOBIOTIC_METABOLISM+0.117
Top 10 suppressed
- MYC_TARGETS_V1-0.675
- MYC_TARGETS_V2-0.613
- E2F_TARGETS-0.597
- DNA_REPAIR-0.575
- UNFOLDED_PROTEIN_RESPONSE-0.560
- G2M_CHECKPOINT-0.553
- PROTEIN_SECRETION-0.513
- OXIDATIVE_PHOSPHORYLATION-0.482
- MTORC1_SIGNALING-0.427
- TGF_BETA_SIGNALING-0.393
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_QV51J756 | Ganglioglioma | — | 0.986 |
| 2 | BS_9F09XV62 | low-grade glioma | — | 0.968 |
| 3 | BS_K5802F84 | pilocytic astrocytoma | — | 0.967 |
| 4 | BS_92VDQ0NE | Ganglioglioma | — | 0.964 |
| 5 | BS_398KYV92 | Meningioma | — | 0.963 |
| 6 | BS_7B89YR6K | EPN | Posterior Fossa EPN | 0.961 |
| 7 | BS_JXNZYGCR | DNET | — | 0.960 |
| 8 | BS_KPT2WPHW | Ganglioglioma | — | 0.958 |
| 9 | BS_6MY8W3H0 | DNET | — | 0.958 |
| 10 | BS_C7N3J4NW | high-grade glioma | — | 0.957 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.514 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.385 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.329 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.299 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.233 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.223 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.172 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.162 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.127 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.117 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.115 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.083 | Inavolisib | — uncovered |
| COAGULATION | 0.076 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.073 | Inavolisib | — uncovered |